search
Back to results

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Primary Purpose

Infections, Meningococcal

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
MenABCWY-2Gen low dose vaccine
MenABCWY-2Gen high dose vaccine
Placebo
MenB vaccine
MenACWY vaccine
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infections, Meningococcal focused on measuring Bexsero, Menveo, Boostrix, MenABCWY-2Gen, Effectiveness, Safety, Invasive Meningococcal Disease, Adolescents and Adults

Eligibility Criteria

10 Years - 50 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

All inclusion criteria are applicable for both study phases, except where specified otherwise.

  • Participants and/or participants' parent(s)/Legally Acceptable Representative(s) (LAR) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the eDiaries, return for follow-up visits).
  • Written or witnessed/thumb printed informed consent obtained from the participant or /parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
  • Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure.
  • Phase I only: A male or female between, and including, 18 and 40 years of age (i.e. 40 years + 364 days) at the time of the first study intervention administration.
  • Phase II (Formulation and Schedule-finding) only: A male or female between, and including, 10 and 25 years of age (i.e. 25 years + 364 days) at the time of the first study intervention administration.
  • Phase II (Sourcing) only: A male or female between, and including, 18 and 50 years of age (i.e. 50 years + 364 days) at the time of the first study intervention administration.
  • Participants who are either unvaccinated with MenACWY vaccine or have received a single previous dose of MenACWY vaccine can participate in the study, if they have received it at least 4 years prior to informed consent and assent as applicable (with the exception of meningococcal C vaccination, if the last dose of MenC was received at ≤24 months of age).
  • Healthy participants as established by medical history and clinical examination before entering into the study.
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate contraception for 1 month prior to study intervention administration, and
    • has a negative pregnancy test on the day of study intervention administration, and
    • has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration.

Exclusion Criteria:

Medical conditions

  • Current or previous, confirmed or suspected disease caused by N. meningitidis.
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment.
  • Progressive, unstable or uncontrolled clinical conditions.
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
  • Are obese at enrolment (e.g. for participants from 20 years of age a body mass index (BMI) ≥ 30 kg/m2, for participants up to 19 years of age a BMI ≥ 95th percentile for age and gender or as applicable per country recommendations).
  • Any neuroinflammatory (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures). History of febrile convulsions should not lead to exclusion.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
  • Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study.
  • Abnormal function or modification of the immune system resulting from:

    • Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).
    • Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 3 months prior to study vaccination until the last blood sampling visit for Phase I and Phase II (Sourcing) and Visit 5 (Day 211) for Phase II (Formulation and Schedule-finding). This will mean prednisone equivalent ≥20 mg/day for adult participants/ ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.
    • Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
    • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -29 to Day 1), or their planned use during the study period.
  • Previous vaccination against any group B meningococcal vaccine at any time prior to informed consent and assent as applicable.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration until the last blood sampling visit for Phase I and Phase II (Sourcing) and Visit 5 (Day 211) for Phase II (Formulation and Schedule-finding).
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) until the last blood sampling visit for Phase I and Phase II (Sourcing) and Visit 5 (Day 211) for Phase II (Formulation and Schedule-finding). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants/ ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).

Other exclusions

  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
  • History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator.
  • Any study personnel or immediate dependents, family, or household member.
  • Phase II (Formulation and Schedule-finding): Child in care.

Sites / Locations

  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site
  • GSK Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Active Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

ABCWY low dose Group

Placebo low dose Group

ABCWY high dose Group

Placebo high dose Group

ABCWY low dose_06 Group

ABCWY low dose_02 Group

ABCWY high dose_06 Group

ABCWY high dose_02 Group

Control Group

ABCWY low dose_01 Group

ABCWY high dose_01 Group

ABCWY low doseS_02 Group

ABCWY high doseS_02 Group

ABCWY low doseS_06 Group

ABCWY high doseS_06 Group

Arm Description

Participants receive MenABCWY-2Gen low dose vaccine and are followed up until Day 211 in study Phase I.

Participants receive NaCl as a control for ABCWY low dose group and are followed up until Day 211 in study Phase I.

Participants receive MenABCWY-2Gen high dose vaccine and are followed up until Day 211 in study Phase I.

Participants receive NaCl as a control for ABCWY high dose group and are followed up until Day 211 in study Phase I.

Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).

Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).

Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).

Participants receive MenABCWY-2Gen high dose vaccine in a 0,2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).

Participants randomized to Control Group receive 2 doses of Bexsero (MenB) vaccine and 1 dose of Menveo (MenACWY), 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).

Participants receive MenABCWY-2Gen low dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).

Participants receive MenABCWY-2Gen high dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).

Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).

Participants receive MenABCWY-2Gen high dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).

Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).

Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).

Outcomes

Primary Outcome Measures

Percentages of participants with solicited administration site events in study Phase I (Safety Lead-in)
The solicited administration site events include injection site pain, erythema (redness), swelling and induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Percentages of participants with solicited administration site events in study Phase I (Safety Lead-in)
Percentages of participants with solicited systemic events in study Phase I (Safety Lead-in)
The solicited systemic events include fever (temperature ≥ 38.0°C), nausea, fatigue, myalgia, arthralgia and headache.
Percentages of participants with solicited systemic events in study Phase I (Safety Lead-in)
Percentages of participants with any unsolicited adverse events (AEs), including all serious adverse events (SAEs), AEs leading to withdrawal and AEs of special interest (AESIs) in study Phase I (Safety Lead-in)
The unsolicited AEs includes any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. "Any" occurrence of the event regardless of the intensity grade. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it.
Percentages of participants with any unsolicited adverse events (AEs), including all serious adverse events (SAEs), AEs leading to withdrawal and AEs of special interest (AESIs) in study Phase I (Safety Lead-in)
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase I (Safety Lead-in)
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it.
Percentages of participants with haematological and biochemical laboratory abnormalities, and changes from the baseline values, in study Phase I (Safety Lead-in)
Haematology and biochemistry assays for safety assessment are performed in all participants in Phase I, in the investigator's laboratory using standard procedures as per local practice.
Percentages of samples with bactericidal serum activity against a panel of 110 randomly selected endemic US N. meningitidis serogroup B invasive disease strains in study Phase II (Formulation and Schedule-finding)
The effectiveness of the MenABCWY-2Gen (low and high dose) vaccine when administered at 0,2- or 0,6-months schedule compared to MenB vaccine administered at 0,6-months schedule, against a panel of 110 randomly selected endemic N. meningitidis serogroup B strains is measured in terms of percentage of samples with bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.
Percentages of participants with a 4-fold rise in hSBA titers against serogroups A, C, W and Y in study Phase II (Formulation and Schedule-finding)
The immune response to the MenABCWY-2Gen (low and high dose) vaccine when administered at 0,2- or 0,6-months schedule compared to MenACWY vaccine (single dose), relative to day 1 in the ABCWY and control groups (0, 6 month schedule) and day 31 in ABCWY (0, 2 month schedule) is measured in terms of percentage of participants achieving a 4-fold rise in hSBA titers against serogroups A, C, W and Y. The 4-fold rise is defined as: -a post-vaccination hSBA titer ≥ 16 for participants with a pre-vaccination hSBA titer < 4, -a post-vaccination hSBA titer ≥ 4 times the lower limit of quantitation (LLOQ) for participants with a pre-vaccination hSBA titer ≥LOD but <LLOQ, and. -a post-vaccination hSBA titer ≥ 4 times the pre-vaccination hSBA titer for participants with a pre-vaccination hSBA titer ≥LLOQ.
Percentages of participants with solicited administration site events in study Phase II (Formulation and Schedule-finding)
The solicited administration site events include injection site pain, erythema (redness), swelling and induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Percentages of participants with solicited administration site events in study Phase II (Formulation and Schedule-finding)
Percentages of participants with solicited administration site events in study Phase II (Formulation and Schedule-finding)
Percentages of participants with solicited systemic events in study Phase II (Formulation and Schedule-finding)
The solicited systemic events include fever (temperature ≥ 38.0°C), nausea, fatigue, myalgia, arthralgia and headache.
Percentages of participants with solicited systemic events in study Phase II (Formulation and Schedule-finding)
Percentages of participants with solicited systemic events in study Phase II (Formulation and Schedule-finding)
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Formulation and Schedule-finding)
The unsolicited AEs includes any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms are reported as an unsolicited adverse event. "Any" occurrence of the event regardless of the intensity grade. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it.
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Formulation and Schedule-finding)
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Formulation and Schedule-finding)
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Formulation and Schedule-Finding)
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it.
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
The solicited administration site events include injection site pain, erythema (redness), swelling and induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
The solicited systemic events include fever (temperature ≥ 38.0°C), nausea, fatigue, myalgia, arthralgia and headache.
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
The unsolicited AEs includes any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. "Any" occurrence of the event regardless of the intensity grade. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it.
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Sourcing)
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it.
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Sourcing)
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Sourcing)

Secondary Outcome Measures

Percentages of serogroup B invasive disease strains killed in each participant sample in study Phase II (Formulation and Schedule-finding)
The percentages of strains killed measured by enc-hSBA against a randomly selected panel of strains and the corresponding exact 2-sided 95% CIs based on Clopper-Pearson method is calculated in all groups at 1 month after the last vaccination of MenABCWY-2Gen (low and high dose) vaccine administered at 0,2 and 0,6-months schedule and of the MenB vaccine administered at 0,6-months schedule.
Percentages of participants with hSBA titers ≥LLOQ for each and all serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
The immune response to MenABCWY-2Gen (low and high dose) administered at 0,2 and 0,6-months schedule and MenB vaccine administered at 0,6-months schedule is evaluated by measuring bactericidal activity using a qualified AO hSBA against a standard panel of serogroup B indicator strains.
Percentages of participants with 4-fold rise in hSBA titers against serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
The immune response to MenABCWY-2Gen (low and high dose) vaccine when administered at 0,2- or 0,6-months schedule and to MenB vaccine administered at 0,6-months schedule, relative to day 1 in ABCWY (0,6 month schedule) and control groups and day 31 in ABCWY (0,2 month schedule) is measured in terms of percentage of participants achieving a 4-fold rise in hSBA titers against serogroup B indicator strains. The calculation is based on Clopper Pearson method. The 4-fold rise is defined as: -a post-vaccination hSBA titer ≥ 16 for participants with a pre-vaccination hSBA titre < 4, -a post-vaccination hSBA titer ≥ 4 times the LLOQ for participants with a pre-vaccination hSBA titer ≥LOD but <LLOQ, and. -a post-vaccination hSBA titer ≥ 4 times the pre-vaccination hSBA titer for participants with a pre-vaccination hSBA titer ≥ LLOQ.
hSBA Geometric mean titers (GMTs) against serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
The immune response to MenABCWY-2Gen (low and high dose) vaccine administered at 0,2 and 0,6-months schedule and to the MenB vaccine administered at 0,6-months schedule against serogroup B indicator strains is determined using hSBA GMTs.The hSBA titers are logarithmically transformed (base10) to fulfil the normal distribution assumption. For each B strains, the GMTs) are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
hSBA Geometric mean ratios (GMRs) against serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
The immune response to the MenABCWY-2Gen (low and high dose) vaccine administered at 0,2 and 0,6-months schedule and to the MenB vaccine administered at 0,6-months schedule against serogroup B indicator strains is determined using hSBA GMRs. The hSBA titers are logarithmically transformed (base10) to fulfil the normal distribution assumption. For each B strains, the GMRs (post-vaccination/ Day 1 (Month 0)) are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
Percentages of participants with hSBA titers ≥ LLOQ for serogroups A, C, W and Y in study Phase II (Formulation and Schedule-finding)
The immune response to MenABCWY-2Gen (low and high dose) vaccine administered at at 0,2 and 0,6-months schedule and MenACWY vaccine administered at 0,6-months schedule is evaluated against serogroups A, C, W and Y . The percentages of participants with hSBA titers ≥ LLOQ and the corresponding exact 2-sided 95% CIs based on Clopper-Pearson method are calculated.
Percentages of participants with a 4-fold rise in hSBA titers against serogroups A, C, W and Y in study Phase II (Formulation and Schedule-finding)
The immune response to the MenABCWY-2Gen (low and high dose) vaccine when administered at 0,6-months schedule, relative to day 1 is measured in terms of percentage of participants achieving a 4-fold rise in hSBA titers against serogroups A, C, W and Y. Serum bactericidal activity against MenACWY will be determined by using a validated AO hSBA. The 4-fold rise is defined as: -a post-vaccination hSBA titre ≥ 16 for participants with a pre-vaccination hSBA titre < 4, -a post-vaccination hSBA titre ≥ 4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥ LOD but < LLOQ, and. -a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ.
hSBA GMTs against serogroups A, C, W and Y
The immune response to the MenABCWY-2Gen (low and high dose) vaccine (0,2- and 0,6-months schedule) and MenACWY vaccine (single dose) is evaluated by hSBA titers which are logarithmically transformed (base10) to fulfil the normal distribution assumption. For each serogroup A, C, W and Y, the GMTs are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
hSBA GMRs against serogroups A, C, W and Y
The hSBA titers groups will be logarithmically transformed (base10) to fulfil the normal distribution assumption. For each serogroup A, C, W and Y, the GMRs (post-vaccination/ Day 1 (Month 0) are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
Immunoglobulin G (IgG) antibodies against serogroups A, C, W and Y
The immune responses to MenABCWY-2Gen (low and high dose) and MenACWY vaccines are evaluated by measuring the total IgG in terms of electrochemiluminescence-based (ECL) multiplex assay Geometric Mean Concentrations (GMCs)

Full Information

First Posted
May 10, 2021
Last Updated
March 17, 2023
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT04886154
Brief Title
A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
Official Title
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 14, 2021 (Actual)
Primary Completion Date
January 19, 2024 (Anticipated)
Study Completion Date
January 19, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the safety, effectiveness and immune response of the meningococcal combined ABCWY vaccine (GSK4023393A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups. The first time-in-human (FTIH), Phase I part of this study will be conducted in healthy adults in a dose-escalating fashion with 2 formulations of the investigational MenABCWY-2Gen vaccine and will serve as a safety lead-in to the Phase II study. The Phase II part of the study will be conducted in 2 parts: The 'formulation and schedule-finding' part will follow in healthy adolescents and young adults and it is designed to select the vaccine formulation and the schedule to be tested in Phase III. The 'blood sourcing' part will be conducted in healthy adults in order to collect sufficient serum samples for the development of assays to be used in the MenABCWY-2Gen vaccine clinical development program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infections, Meningococcal
Keywords
Bexsero, Menveo, Boostrix, MenABCWY-2Gen, Effectiveness, Safety, Invasive Meningococcal Disease, Adolescents and Adults

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
The Phase I safety lead-in will follow a staggered enrolment Phase II will start only after a positive outcome from the internal Safety Review Committee (iSRC) review of the safety data from participants receiving vaccination in Phase I of the study.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Data will be collected in an observer-blind manner.
Allocation
Randomized
Enrollment
1258 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ABCWY low dose Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen low dose vaccine and are followed up until Day 211 in study Phase I.
Arm Title
Placebo low dose Group
Arm Type
Placebo Comparator
Arm Description
Participants receive NaCl as a control for ABCWY low dose group and are followed up until Day 211 in study Phase I.
Arm Title
ABCWY high dose Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen high dose vaccine and are followed up until Day 211 in study Phase I.
Arm Title
Placebo high dose Group
Arm Type
Placebo Comparator
Arm Description
Participants receive NaCl as a control for ABCWY high dose group and are followed up until Day 211 in study Phase I.
Arm Title
ABCWY low dose_06 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
Arm Title
ABCWY low dose_02 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
Arm Title
ABCWY high dose_06 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
Arm Title
ABCWY high dose_02 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen high dose vaccine in a 0,2 month schedule and 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
Participants randomized to Control Group receive 2 doses of Bexsero (MenB) vaccine and 1 dose of Menveo (MenACWY), 1 dose of NaCl and are followed up until Day 541 in study Phase II (Formulation and Schedule-finding).
Arm Title
ABCWY low dose_01 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen low dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
Arm Title
ABCWY high dose_01 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen high dose vaccine in a 0,1 month schedule and are followed up until Day 211 in study Phase II (Sourcing).
Arm Title
ABCWY low doseS_02 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen low dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
Arm Title
ABCWY high doseS_02 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen high dose vaccine in a 0, 2 month schedule and are followed up until Day 241 in study Phase II (Sourcing).
Arm Title
ABCWY low doseS_06 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen low dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
Arm Title
ABCWY high doseS_06 Group
Arm Type
Experimental
Arm Description
Participants receive MenABCWY-2Gen high dose vaccine in a 0, 6 month schedule and are followed up until Day 361 in study Phase II (Sourcing).
Intervention Type
Combination Product
Intervention Name(s)
MenABCWY-2Gen low dose vaccine
Intervention Description
MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
Intervention Type
Combination Product
Intervention Name(s)
MenABCWY-2Gen high dose vaccine
Intervention Description
MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
Intervention Type
Combination Product
Intervention Name(s)
Placebo
Other Intervention Name(s)
NaCl, saline solution
Intervention Description
Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
Intervention Type
Combination Product
Intervention Name(s)
MenB vaccine
Other Intervention Name(s)
GSK's meningococcal group B vaccine, Bexsero
Intervention Description
MenB vaccine is administered intramuscularly in the deltoid region of the non-dominant arm, whenever it's possible, as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
Intervention Type
Biological
Intervention Name(s)
MenACWY vaccine
Other Intervention Name(s)
GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo
Intervention Description
MenACWY vaccine is administered intramuscularly in the deltoid region of the dominant arm as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
Primary Outcome Measure Information:
Title
Percentages of participants with solicited administration site events in study Phase I (Safety Lead-in)
Description
The solicited administration site events include injection site pain, erythema (redness), swelling and induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with solicited administration site events in study Phase I (Safety Lead-in)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 31
Title
Percentages of participants with solicited systemic events in study Phase I (Safety Lead-in)
Description
The solicited systemic events include fever (temperature ≥ 38.0°C), nausea, fatigue, myalgia, arthralgia and headache.
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with solicited systemic events in study Phase I (Safety Lead-in)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 31
Title
Percentages of participants with any unsolicited adverse events (AEs), including all serious adverse events (SAEs), AEs leading to withdrawal and AEs of special interest (AESIs) in study Phase I (Safety Lead-in)
Description
The unsolicited AEs includes any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. "Any" occurrence of the event regardless of the intensity grade. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it.
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with any unsolicited adverse events (AEs), including all serious adverse events (SAEs), AEs leading to withdrawal and AEs of special interest (AESIs) in study Phase I (Safety Lead-in)
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 31
Title
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase I (Safety Lead-in)
Description
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it.
Time Frame
Throughout the study period (Day 1 through Day 211)
Title
Percentages of participants with haematological and biochemical laboratory abnormalities, and changes from the baseline values, in study Phase I (Safety Lead-in)
Description
Haematology and biochemistry assays for safety assessment are performed in all participants in Phase I, in the investigator's laboratory using standard procedures as per local practice.
Time Frame
At Day 8 after the first vaccination
Title
Percentages of samples with bactericidal serum activity against a panel of 110 randomly selected endemic US N. meningitidis serogroup B invasive disease strains in study Phase II (Formulation and Schedule-finding)
Description
The effectiveness of the MenABCWY-2Gen (low and high dose) vaccine when administered at 0,2- or 0,6-months schedule compared to MenB vaccine administered at 0,6-months schedule, against a panel of 110 randomly selected endemic N. meningitidis serogroup B strains is measured in terms of percentage of samples with bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.
Time Frame
At Day 211 (1 month after the last vaccination)
Title
Percentages of participants with a 4-fold rise in hSBA titers against serogroups A, C, W and Y in study Phase II (Formulation and Schedule-finding)
Description
The immune response to the MenABCWY-2Gen (low and high dose) vaccine when administered at 0,2- or 0,6-months schedule compared to MenACWY vaccine (single dose), relative to day 1 in the ABCWY and control groups (0, 6 month schedule) and day 31 in ABCWY (0, 2 month schedule) is measured in terms of percentage of participants achieving a 4-fold rise in hSBA titers against serogroups A, C, W and Y. The 4-fold rise is defined as: -a post-vaccination hSBA titer ≥ 16 for participants with a pre-vaccination hSBA titer < 4, -a post-vaccination hSBA titer ≥ 4 times the lower limit of quantitation (LLOQ) for participants with a pre-vaccination hSBA titer ≥LOD but <LLOQ, and. -a post-vaccination hSBA titer ≥ 4 times the pre-vaccination hSBA titer for participants with a pre-vaccination hSBA titer ≥LLOQ.
Time Frame
At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY groups and at Day 31 the Control group)
Title
Percentages of participants with solicited administration site events in study Phase II (Formulation and Schedule-finding)
Description
The solicited administration site events include injection site pain, erythema (redness), swelling and induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with solicited administration site events in study Phase II (Formulation and Schedule-finding)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 121
Title
Percentages of participants with solicited administration site events in study Phase II (Formulation and Schedule-finding)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 181
Title
Percentages of participants with solicited systemic events in study Phase II (Formulation and Schedule-finding)
Description
The solicited systemic events include fever (temperature ≥ 38.0°C), nausea, fatigue, myalgia, arthralgia and headache.
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with solicited systemic events in study Phase II (Formulation and Schedule-finding)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 121
Title
Percentages of participants with solicited systemic events in study Phase II (Formulation and Schedule-finding)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 181
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Formulation and Schedule-finding)
Description
The unsolicited AEs includes any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms are reported as an unsolicited adverse event. "Any" occurrence of the event regardless of the intensity grade. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it.
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Formulation and Schedule-finding)
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 121
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Formulation and Schedule-finding)
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 181
Title
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Formulation and Schedule-Finding)
Description
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it.
Time Frame
Throughout the study period (Day 1 through Day 541)
Title
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Description
The solicited administration site events include injection site pain, erythema (redness), swelling and induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 31
Title
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 61
Title
Percentages of participants with solicited administration site events in study Phase II (Sourcing)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 181
Title
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Description
The solicited systemic events include fever (temperature ≥ 38.0°C), nausea, fatigue, myalgia, arthralgia and headache.
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 31
Title
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 61
Title
Percentages of participants with solicited systemic events in study Phase II (Sourcing)
Time Frame
During the 7 days (including the day of vaccination) following vaccination at Day 181
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Description
The unsolicited AEs includes any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. "Any" occurrence of the event regardless of the intensity grade. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it.
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 1
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 31
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 61
Title
Percentages of participants with any unsolicited AEs (including all SAEs, AEs leading to withdrawal, and AESIs) in study Phase II (Sourcing)
Time Frame
During the 30 days (including the day of vaccination) following vaccination at Day 181
Title
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Sourcing)
Description
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it.
Time Frame
Throughout the study period (Day 1 through Day 211)
Title
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Sourcing)
Time Frame
Throughout the study period (Day 1 through Day 241)
Title
Percentages of participants with SAEs, AEs leading to withdrawal and AESIs in study Phase II (Sourcing)
Time Frame
Throughout the study period (Day 1 through Day 361)
Secondary Outcome Measure Information:
Title
Percentages of serogroup B invasive disease strains killed in each participant sample in study Phase II (Formulation and Schedule-finding)
Description
The percentages of strains killed measured by enc-hSBA against a randomly selected panel of strains and the corresponding exact 2-sided 95% CIs based on Clopper-Pearson method is calculated in all groups at 1 month after the last vaccination of MenABCWY-2Gen (low and high dose) vaccine administered at 0,2 and 0,6-months schedule and of the MenB vaccine administered at 0,6-months schedule.
Time Frame
At Day 211 (1 month after the last vaccination)
Title
Percentages of participants with hSBA titers ≥LLOQ for each and all serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
Description
The immune response to MenABCWY-2Gen (low and high dose) administered at 0,2 and 0,6-months schedule and MenB vaccine administered at 0,6-months schedule is evaluated by measuring bactericidal activity using a qualified AO hSBA against a standard panel of serogroup B indicator strains.
Time Frame
At Day 1 in ABCWY (0,6-months) and Control groups, Day 31 in ABCWY groups (0,2-months) and Day 211 in all study groups
Title
Percentages of participants with 4-fold rise in hSBA titers against serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
Description
The immune response to MenABCWY-2Gen (low and high dose) vaccine when administered at 0,2- or 0,6-months schedule and to MenB vaccine administered at 0,6-months schedule, relative to day 1 in ABCWY (0,6 month schedule) and control groups and day 31 in ABCWY (0,2 month schedule) is measured in terms of percentage of participants achieving a 4-fold rise in hSBA titers against serogroup B indicator strains. The calculation is based on Clopper Pearson method. The 4-fold rise is defined as: -a post-vaccination hSBA titer ≥ 16 for participants with a pre-vaccination hSBA titre < 4, -a post-vaccination hSBA titer ≥ 4 times the LLOQ for participants with a pre-vaccination hSBA titer ≥LOD but <LLOQ, and. -a post-vaccination hSBA titer ≥ 4 times the pre-vaccination hSBA titer for participants with a pre-vaccination hSBA titer ≥ LLOQ.
Time Frame
At Day 211 (1 month after the last vaccination)
Title
hSBA Geometric mean titers (GMTs) against serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
Description
The immune response to MenABCWY-2Gen (low and high dose) vaccine administered at 0,2 and 0,6-months schedule and to the MenB vaccine administered at 0,6-months schedule against serogroup B indicator strains is determined using hSBA GMTs.The hSBA titers are logarithmically transformed (base10) to fulfil the normal distribution assumption. For each B strains, the GMTs) are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
Time Frame
At Day 1 in ABCWY groups (0,6-months) and Control groups, Day 31 in ABCWY groups (0,2-months) and Day 211 in all study groups
Title
hSBA Geometric mean ratios (GMRs) against serogroup B indicator strains in study Phase II (Formulation and Schedule-finding)
Description
The immune response to the MenABCWY-2Gen (low and high dose) vaccine administered at 0,2 and 0,6-months schedule and to the MenB vaccine administered at 0,6-months schedule against serogroup B indicator strains is determined using hSBA GMRs. The hSBA titers are logarithmically transformed (base10) to fulfil the normal distribution assumption. For each B strains, the GMRs (post-vaccination/ Day 1 (Month 0)) are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
Time Frame
At Day 211 in all study groups versus Day 1 in ABCWY (0,6-months) and Control groups and Day 31 in ABCWY groups (0,2-months)
Title
Percentages of participants with hSBA titers ≥ LLOQ for serogroups A, C, W and Y in study Phase II (Formulation and Schedule-finding)
Description
The immune response to MenABCWY-2Gen (low and high dose) vaccine administered at at 0,2 and 0,6-months schedule and MenACWY vaccine administered at 0,6-months schedule is evaluated against serogroups A, C, W and Y . The percentages of participants with hSBA titers ≥ LLOQ and the corresponding exact 2-sided 95% CIs based on Clopper-Pearson method are calculated.
Time Frame
At Day 1 in ABCWY (0,6-months) and Control groups, Day 31 in ABCWY groups (0,2- and 0,6-months), Day 211 (1 month after the last vaccination) in all ABCWY groups and Day 31 (1 month after the MenACWY vaccination) in Control group
Title
Percentages of participants with a 4-fold rise in hSBA titers against serogroups A, C, W and Y in study Phase II (Formulation and Schedule-finding)
Description
The immune response to the MenABCWY-2Gen (low and high dose) vaccine when administered at 0,6-months schedule, relative to day 1 is measured in terms of percentage of participants achieving a 4-fold rise in hSBA titers against serogroups A, C, W and Y. Serum bactericidal activity against MenACWY will be determined by using a validated AO hSBA. The 4-fold rise is defined as: -a post-vaccination hSBA titre ≥ 16 for participants with a pre-vaccination hSBA titre < 4, -a post-vaccination hSBA titre ≥ 4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥ LOD but < LLOQ, and. -a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ.
Time Frame
At Day 31 (1 month after the first MenABCWY-2Gen vaccination)
Title
hSBA GMTs against serogroups A, C, W and Y
Description
The immune response to the MenABCWY-2Gen (low and high dose) vaccine (0,2- and 0,6-months schedule) and MenACWY vaccine (single dose) is evaluated by hSBA titers which are logarithmically transformed (base10) to fulfil the normal distribution assumption. For each serogroup A, C, W and Y, the GMTs are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
Time Frame
At Day 1 in ABCWY groups (0,6-months) and Control group, Day 31 in ABCWY groups (0,2-months and 0,6-moths), Day 211 in all ABCWY groups and Day 31 in the Control group
Title
hSBA GMRs against serogroups A, C, W and Y
Description
The hSBA titers groups will be logarithmically transformed (base10) to fulfil the normal distribution assumption. For each serogroup A, C, W and Y, the GMRs (post-vaccination/ Day 1 (Month 0) are calculated with their associated 2-sided 95% CIs, by exponentiating the corresponding log-transformed means and their 95% CIs.
Time Frame
At Day 31 versus Day 1 in ABCWY (0,6-months) and Control groups, Day 211 versus Day 1 in ABCWY (0,6-months) groups and Day 211 versus Day 31 in ABCWY (0,2-months) groups
Title
Immunoglobulin G (IgG) antibodies against serogroups A, C, W and Y
Description
The immune responses to MenABCWY-2Gen (low and high dose) and MenACWY vaccines are evaluated by measuring the total IgG in terms of electrochemiluminescence-based (ECL) multiplex assay Geometric Mean Concentrations (GMCs)
Time Frame
At Day 1 in ABCWY groups (0,6-months) and Control groups, Day 31 in ABCWY groups (0,2-months) and Day 31 in the ABCWY groups (0,6-months) and in Control group, and Day 211 for all ABCWY groups

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All inclusion criteria are applicable for both study phases, except where specified otherwise. Participants and/or participants' parent(s)/Legally Acceptable Representative(s) (LAR) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the eDiaries, return for follow-up visits). Written or witnessed/thumb printed informed consent obtained from the participant or /parent(s)/LAR(s) of the participant prior to performance of any study specific procedure. Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure. Phase I only: A male or female between, and including, 18 and 40 years of age (i.e. 40 years + 364 days) at the time of the first study intervention administration. Phase II (Formulation and Schedule-finding) only: A male or female between, and including, 10 and 25 years of age (i.e. 25 years + 364 days) at the time of the first study intervention administration. Phase II (Sourcing) only: A male or female between, and including, 18 and 50 years of age (i.e. 50 years + 364 days) at the time of the first study intervention administration. Participants who are either unvaccinated with MenACWY vaccine or have received a single previous dose of MenACWY vaccine can participate in the study, if they have received it at least 4 years prior to informed consent and assent as applicable (with the exception of meningococcal C vaccination, if the last dose of MenC was received at ≤24 months of age). Healthy participants as established by medical history and clinical examination before entering into the study. Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. Female participants of childbearing potential may be enrolled in the study, if the participant: has practiced adequate contraception for 1 month prior to study intervention administration, and has a negative pregnancy test on the day of study intervention administration, and has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration. Exclusion Criteria: Medical conditions Current or previous, confirmed or suspected disease caused by N. meningitidis. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment. Progressive, unstable or uncontrolled clinical conditions. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws. Are obese at enrolment (e.g. for participants from 20 years of age a body mass index (BMI) ≥ 30 kg/m2, for participants up to 19 years of age a BMI ≥ 95th percentile for age and gender or as applicable per country recommendations). Any neuroinflammatory (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures). History of febrile convulsions should not lead to exclusion. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions. Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study. Abnormal function or modification of the immune system resulting from: Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes). Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 3 months prior to study vaccination until the last blood sampling visit for Phase I and Phase II (Sourcing) and Visit 5 (Day 211) for Phase II (Formulation and Schedule-finding). This will mean prednisone equivalent ≥20 mg/day for adult participants/ ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination. Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab). Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. Prior/Concomitant therapy Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -29 to Day 1), or their planned use during the study period. Previous vaccination against any group B meningococcal vaccine at any time prior to informed consent and assent as applicable. Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration until the last blood sampling visit for Phase I and Phase II (Sourcing) and Visit 5 (Day 211) for Phase II (Formulation and Schedule-finding). Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) until the last blood sampling visit for Phase I and Phase II (Sourcing) and Visit 5 (Day 211) for Phase II (Formulation and Schedule-finding). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants/ ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed. Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). Other exclusions Pregnant or lactating female. Female planning to become pregnant or planning to discontinue contraceptive precautions. History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator. Any study personnel or immediate dependents, family, or household member. Phase II (Formulation and Schedule-finding): Child in care.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Banning
State/Province
California
ZIP/Postal Code
92220
Country
United States
Facility Name
GSK Investigational Site
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80922
Country
United States
Facility Name
GSK Investigational Site
City
Longmont
State/Province
Colorado
ZIP/Postal Code
80501
Country
United States
Facility Name
GSK Investigational Site
City
Doral
State/Province
Florida
ZIP/Postal Code
33175
Country
United States
Facility Name
GSK Investigational Site
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
GSK Investigational Site
City
Meridian
State/Province
Idaho
ZIP/Postal Code
82642
Country
United States
Facility Name
GSK Investigational Site
City
Nampa
State/Province
Idaho
ZIP/Postal Code
83686
Country
United States
Facility Name
GSK Investigational Site
City
Oak Brook
State/Province
Illinois
ZIP/Postal Code
60523
Country
United States
Facility Name
GSK Investigational Site
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65802
Country
United States
Facility Name
GSK Investigational Site
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68516
Country
United States
Facility Name
GSK Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
GSK Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
Facility Name
GSK Investigational Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29414
Country
United States
Facility Name
GSK Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
GSK Investigational Site
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
GSK Investigational Site
City
Fortitude Valley
State/Province
Queensland
ZIP/Postal Code
4006
Country
Australia
Facility Name
GSK Investigational Site
City
Taringa
State/Province
Queensland
ZIP/Postal Code
4068
Country
Australia
Facility Name
GSK Investigational Site
City
Tarragindi
State/Province
Queensland
ZIP/Postal Code
4121
Country
Australia
Facility Name
GSK Investigational Site
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
GSK Investigational Site
City
Spearwood
State/Province
Western Australia
ZIP/Postal Code
6163
Country
Australia
Facility Name
GSK Investigational Site
City
Bruxelles
ZIP/Postal Code
1000
Country
Belgium
Facility Name
GSK Investigational Site
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
GSK Investigational Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
GSK Investigational Site
City
Gozée
ZIP/Postal Code
6534
Country
Belgium
Facility Name
GSK Investigational Site
City
Salvador
State/Province
Bahía
ZIP/Postal Code
40415-006
Country
Brazil
Facility Name
GSK Investigational Site
City
Higienópolis
State/Province
São Paulo
ZIP/Postal Code
01227-200
Country
Brazil
Facility Name
GSK Investigational Site
City
Sao Jose do Rio Preto
State/Province
São Paulo
ZIP/Postal Code
15090-000
Country
Brazil
Facility Name
GSK Investigational Site
City
Rio de Janeiro
ZIP/Postal Code
20241-180
Country
Brazil
Facility Name
GSK Investigational Site
City
São Paulo
ZIP/Postal Code
04266-010
Country
Brazil
Facility Name
GSK Investigational Site
City
Helsinki
ZIP/Postal Code
00180
Country
Finland
Facility Name
GSK Investigational Site
City
Turku
ZIP/Postal Code
20100
Country
Finland
Facility Name
GSK Investigational Site
City
Turku
ZIP/Postal Code
20520
Country
Finland
Facility Name
GSK Investigational Site
City
Bydgoszcz
ZIP/Postal Code
85-048
Country
Poland
Facility Name
GSK Investigational Site
City
Bydgoszcz
ZIP/Postal Code
85-796
Country
Poland
Facility Name
GSK Investigational Site
City
Elblag
ZIP/Postal Code
82-300
Country
Poland
Facility Name
GSK Investigational Site
City
Katowice
ZIP/Postal Code
40-600
Country
Poland
Facility Name
GSK Investigational Site
City
Katowice
ZIP/Postal Code
40-648
Country
Poland
Facility Name
GSK Investigational Site
City
Krakow
ZIP/Postal Code
30-348
Country
Poland
Facility Name
GSK Investigational Site
City
Krakow
ZIP/Postal Code
30-644
Country
Poland
Facility Name
GSK Investigational Site
City
Lubon
ZIP/Postal Code
62-030
Country
Poland
Facility Name
GSK Investigational Site
City
Siemianowice Slaskie
ZIP/Postal Code
41103
Country
Poland
Facility Name
GSK Investigational Site
City
Tarnow
ZIP/Postal Code
33-100
Country
Poland
Facility Name
GSK Investigational Site
City
Torun
ZIP/Postal Code
87-100
Country
Poland
Facility Name
GSK Investigational Site
City
Trzebnica
ZIP/Postal Code
55-100
Country
Poland
Facility Name
GSK Investigational Site
City
Warsaw
ZIP/Postal Code
00-635
Country
Poland
Facility Name
GSK Investigational Site
City
Warszawa
ZIP/Postal Code
02-647
Country
Poland
Facility Name
GSK Investigational Site
City
Warszawa
ZIP/Postal Code
02-793
Country
Poland
Facility Name
GSK Investigational Site
City
Wroclaw
ZIP/Postal Code
50368
Country
Poland
Facility Name
GSK Investigational Site
City
Borås
ZIP/Postal Code
SE-506 30
Country
Sweden
Facility Name
GSK Investigational Site
City
Karlskrona
ZIP/Postal Code
SE-371 79
Country
Sweden
Facility Name
GSK Investigational Site
City
Stockholm
ZIP/Postal Code
SE-113 61
Country
Sweden
Facility Name
GSK Investigational Site
City
Umeå
ZIP/Postal Code
SE-901 85
Country
Sweden
Facility Name
GSK Investigational Site
City
Örebro
ZIP/Postal Code
SE-703 62
Country
Sweden
Facility Name
GSK Investigational Site
City
Istanbul
ZIP/Postal Code
34742
Country
Turkey
Facility Name
GSK Investigational Site
City
Kocaeli
ZIP/Postal Code
41380
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD for this study will be made available via the Clinical Study Data Request site.
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Learn more about this trial

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

We'll reach out to this number within 24 hrs